Clinically benign multiple sclerosis despite large T2 lesion load: Can we explain this paradox?

Magnetic resonance imaging (MRI) techniques such as magnetization transfer imaging and magnetic resonance spectroscopy (MRS) may reveal otherwise undetectable tissue damage in multiple sclerosis (MS) and can serve to explain more severe disability than expected from conventional MRI. That an inverse situation may exist where non-conventional quantitative MRI and MRS metrics would indicate less abnormality than expected from T2 lesion load to explain preserved clinical functioning was hypothesized. Quantitative MRI and MRS were obtained in 13 consecutive patients with clinically benign MS (BMS; mean age 44 ± 9 years) despite large T 2 lesion load and in 15 patients with secondary progressive MS (SPMS; mean age 47 ± 6 years) matched for disease duration. The magnetization transfer ratio (MTR), magnetization transfer rate (k for), brain parenchymal fraction (BPF) and brain metabolite concentrations from proton MRS were determined. BMS patients were significantly less disabled than their SPMS counterparts (mean expanded disability status score: 2.1 ± 1.1 versus 6.2 ± 1.1; P < 0.001) and had an even somewhat higher mean T2 lesion load (41.2 ± 27.1 versus 27.9 ± 24.8 cm3; P = 0.19). Normal appearing brain tissue histogram metrics for MTR and k for, mean MTR and k for of MS lesions and mean BPF were similar in BMS and SPMS patients. Levels of N-acetyl-aspartate, choline and myoinositol were comparable between groups. This study thus failed to explain the preservation of function in our BMS patients with large T2 lesion load by a higher morphologic or metabolic integrity of the brain parenchyma. Functional compensation must come from other mechanisms such as brain plasticity. Multiple Sclerosis 2008; 14: 205—211. http://msj.sagepub.com

[1]  D.L. Plummer,et al.  DispImage: Un mezzo di analisi e presentazione per iconografia medica , 1992 .

[2]  D Origgi,et al.  Benign versus secondary-progressive multiple sclerosis: the potential role of proton MR spectroscopy in defining the nature of disability. , 1998, AJNR. American journal of neuroradiology.

[3]  M. Filippi,et al.  Cortical adaptation in patients with MS: a cross-sectional functional MRI study of disease phenotypes , 2005, The Lancet Neurology.

[4]  R. Bakshi,et al.  Measurement of Brain and Spinal Cord Atrophy by Magnetic Resonance Imaging as a Tool to Monitor Multiple Sclerosis , 2005, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[5]  M. Filippi,et al.  MRI results from the European Study on Intravenous Immunoglobulin in Secondary Progressive Multiple Sclerosis (ESIMS) , 2005, Multiple sclerosis.

[6]  M. Battaglini,et al.  Brain damage as detected by magnetization transfer imaging is less pronounced in benign than in early relapsing multiple sclerosis. , 2006, Brain : a journal of neurology.

[7]  T Locatelli,et al.  Brain magnetic resonance imaging and multimodal evoked potentials in benign and secondary progressive multiple sclerosis. , 1995, Journal of neurology, neurosurgery, and psychiatry.

[8]  Sridar Narayanan,et al.  Axonal Damage in Multiple Sclerosis Patients with High versus Low Expanded Disability Status Scale Score , 2004, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[9]  Frederik Barkhof,et al.  Grey matter pathology in multiple sclerosis , 2008, The Lancet Neurology.

[10]  P M Matthews,et al.  Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. , 2001, Archives of neurology.

[11]  A. Thompson,et al.  Cord atrophy separates early primary progressive and relapsing remitting multiple sclerosis , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[12]  Massimo Filippi,et al.  The use of quantitative magnetic-resonance-based techniques to monitor the evolution of multiple sclerosis , 2003, The Lancet Neurology.

[13]  S. Reingold,et al.  The role of magnetic resonance techniques in understanding and managing multiple sclerosis. , 1998, Brain : a journal of neurology.

[14]  C. Mainero,et al.  Correlates of MS disability assessed in vivo using aggregates of MR quantities , 2001, Neurology.

[15]  F. Fazekas,et al.  Discrimination of white matter lesions and multiple sclerosis plaques by short echo quantitative 1H—magnetic resonance spectroscopy , 2005, Journal of Neurology.

[16]  M Rovaris,et al.  Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. , 2003, Brain : a journal of neurology.

[17]  P. Gallo,et al.  The HLA-DR13 haplotype is associated with “benign” multiple sclerosis in northeast Italy , 2001, Neurology.

[18]  D. Li,et al.  Benign versus chronic progressive multiple sclerosis: Magnetic resonance imaging features , 1989, Annals of neurology.

[19]  M. Filippi Magnetization transfer MRI in multiple sclerosis and other central nervous system disorders , 2003, European journal of neurology.

[20]  J. Kurtzke Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[21]  G. Barker,et al.  Effect of interferon‐β1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: Results of a European multicenter, randomized, double‐blind, placebo‐controlled trial , 1999 .

[22]  Antonio Federico,et al.  Diffuse axonal and tissue injury in patients with multiple sclerosis with low cerebral lesion load and no disability. , 2002, Archives of neurology.

[23]  D. Arnold,et al.  The role of MRS and fMRI in multiple sclerosis. , 2006, Advances in neurology.

[24]  V. Haughton,et al.  Correlation of magnetic resonance imaging with neuropsychological testing in multiple sclerosis , 1989, Neurology.

[25]  F. Barkhof The clinico‐radiological paradox in multiple sclerosis revisited , 2002, Current opinion in neurology.

[26]  C. Enzinger,et al.  Lower Levels of N-Acetylaspartate in Multiple Sclerosis Patients With the Apolipoprotein E ϵ4 Allele , 2003 .

[27]  A. J. Thompson,et al.  Magnetic resonance studies of abnormalities in the normal appearing white matter and grey matter in multiple sclerosis , 2003, Journal of Neurology.

[28]  Frederik Barkhof,et al.  MRI in multiple sclerosis: correlation with expanded disability status scale (EDSS) , 1999, Multiple sclerosis.

[29]  J. Geurts,et al.  Grey matter pathology in multiple sclerosis , 2006, Acta neurologica Scandinavica. Supplementum.

[30]  G. Barker,et al.  Magnetisation transfer ratio: a robust measure of myelin content in post-mortem multiple sclerosis brain , 2004 .

[31]  G J Barker,et al.  Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. European Study Group on Interferon-beta1b in secondary progressive multiple sclerosis. , 1999, Annals of neurology.

[32]  D. Li,et al.  Randomized controlled trial of interferon-beta-1a in secondary progressive MS , 2001, Neurology.

[33]  Estimation of magnetization transfer rates from PACE experiments with pulsed RF saturation , 2000, Journal of magnetic resonance imaging : JMRI.

[34]  L. Blumhardt,et al.  The relationship of brain and cervical cord volume to disability in clinical subtypes of multiple sclerosis: a three‐dimensional MRI study , 2003, Acta neurologica Scandinavica.

[35]  D. Arnold,et al.  Magnetic resonance techniques for the in vivo assessment of multiple sclerosis pathology: Consensus report of the white matter study group , 2005, Journal of magnetic resonance imaging : JMRI.

[36]  J. De Keyser,et al.  Benign course in multiple sclerosis: a review , 2006, Acta neurologica Scandinavica.

[37]  G J Barker,et al.  Disability in multiple sclerosis is related to normal appearing brain tissue MTR histogram abnormalities , 2003, Multiple sclerosis.

[38]  Lublin Fd,et al.  Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. , 1996 .

[39]  S. Provencher Estimation of metabolite concentrations from localized in vivo proton NMR spectra , 1993, Magnetic resonance in medicine.

[40]  P. Matthews,et al.  Normalized Accurate Measurement of Longitudinal Brain Change , 2001, Journal of computer assisted tomography.

[41]  R Stollberger,et al.  T1 maps from shifted spin echoes and stimulated echoes , 2001, Magnetic resonance in medicine.

[42]  S Ropele,et al.  Quantitative magnetization transfer imaging of pre-lesional white-matter changes in multiple sclerosis , 2002, Multiple sclerosis.

[43]  Nick C Fox,et al.  Magnetic resonance imaging measures of brain atrophy in multiple sclerosis , 2006, Journal of magnetic resonance imaging : JMRI.

[44]  J S Wolinsky,et al.  EFNS guidelines on the use of neuroimaging in the management of multiple sclerosis , 2006, European journal of neurology.